GlassScriptPhysician profile
Michael A Hoosier
NPI 1952850604
$5,698.88
in general payments reported to CMS, 2019-2025
20 companies · $2,559 in 2025
The $2,559 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $744 · 2022: $499 · 2023: $634 · 2024: $1,263 · 2025: $2,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,287 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,287.36 |
| Education | $168.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,381.95 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $548.10 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $523.66 | 2023-2025 | Sotyktu |
| Incyte Corporation | $460.40 | 2021-2025 | Opzelura, Opzelura |
| Nevro Corp. | $317.91 | 2021-2023 | Senza |
| Lilly USA, LLC | $307.66 | 2021-2025 | Ebglyss, Taltz |
| Genzyme Corporation | $241.93 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $238.68 | 2021-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $238.14 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $215.19 | 2024-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $204.56 | 2021-2023 | Ilumya |
| Botanix Sb INC | $202.51 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $191.44 | 2023-2025 | |
| Pfizer INC. | $168.13 | 2023-2025 | |
| Abbvie INC. | $139.15 | 2021-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $97.71 | 2025 | Bimzelx |
| Dermavant Sciences, INC. | $83.40 | 2024 | Vtama |
| Janssen Scientific Affairs, LLC | $68.62 | 2021 | |
| Biofrontera INC. | $57.76 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $11.98 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hoosier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.